273 related articles for article (PubMed ID: 30348087)
1. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
Bader C; Cossin S; Maillard A; Bénard A
BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
[TBL] [Abstract][Full Text] [Related]
2. Uncertainty and the Value of Information in Risk Prediction Modeling.
Sadatsafavi M; Yoon Lee T; Gustafson P
Med Decis Making; 2022 Jul; 42(5):661-671. PubMed ID: 35209762
[TBL] [Abstract][Full Text] [Related]
3. Two-level resampling as a novel method for the calculation of the expected value of sample information in economic trials.
Sadatsafavi M; Marra C; Bryan S
Health Econ; 2013 Jul; 22(7):877-82. PubMed ID: 22933363
[TBL] [Abstract][Full Text] [Related]
4. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
5. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
6. Sample size determination for cost-effectiveness trials.
Willan AR
Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
8. Value-of-Information Analysis for External Validation of Risk Prediction Models.
Sadatsafavi M; Lee TY; Wynants L; Vickers AJ; Gustafson P
Med Decis Making; 2023 Jul; 43(5):564-575. PubMed ID: 37345680
[TBL] [Abstract][Full Text] [Related]
9. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
10. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Sarker SJ; Whitehead A; Khan I
Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people.
Galani C; Al M; Schneider H; Rutten FF
Value Health; 2008; 11(3):424-34. PubMed ID: 18179675
[TBL] [Abstract][Full Text] [Related]
12. Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information.
Price MJ; Welton NJ; Briggs AH; Ades AE
Value Health; 2011; 14(2):205-18. PubMed ID: 21402291
[TBL] [Abstract][Full Text] [Related]
13. An optimization approach to calculating sample sizes with binary responses.
Maroufy V; Marriott P; Pezeshk H
J Biopharm Stat; 2014; 24(4):715-31. PubMed ID: 24697665
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.
Briggs AH
Int J Technol Assess Health Care; 2001; 17(1):69-82. PubMed ID: 11329846
[TBL] [Abstract][Full Text] [Related]
15. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.
Müller D; Pullenayegum E; Gandjour A
Eur J Health Econ; 2015 Mar; 16(2):219-23. PubMed ID: 24840608
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
17. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
[TBL] [Abstract][Full Text] [Related]
18. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.
Hoomans T; Fenwick EA; Palmer S; Claxton K
Value Health; 2009; 12(2):315-24. PubMed ID: 18657098
[TBL] [Abstract][Full Text] [Related]
19. Simulation sample sizes for Monte Carlo partial EVPI calculations.
Oakley JE; Brennan A; Tappenden P; Chilcott J
J Health Econ; 2010 May; 29(3):468-77. PubMed ID: 20378190
[TBL] [Abstract][Full Text] [Related]
20. Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression.
Heath A; Manolopoulou I; Baio G
Med Decis Making; 2019 May; 39(4):346-358. PubMed ID: 31161867
[No Abstract] [Full Text] [Related]
[Next] [New Search]
